In my March article, "Why Pfizer Remains A Strong Buy In 2026", I mainly discussed Pfizer's Q4 earnings ( PFE) and the ...

Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with mid-stage clinical data for a ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.

Pfizer announced on Sept. 30 it will participate in a new government direct-to-consumer drug sale website. TrumpRx, which is expected to launch at the beginning of next year, will allow patients to ...

Learn more about Pfizer Inc.'s (PFE) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether ...

Pfizer and President Donald Trump are partnering to launch a direct-to-consumer drug sales website called TrumpRx. As part of the deal, Pfizer will invest in U.S. manufacturing and receive a ...

(Reuters) -Pfizer said on Thursday it completed an acquisition worth up to $10 billion of biotech firm Metsera after winning shareholder approval, securing a path into the fast-growing obesity ...

Pfizer Inc. said a new version of its bestselling Prevnar vaccine may provide infants with better protection against common ...

The healthcare giant has been investing heavily in its future growth.